LeadStory

CNBC

Europe's pharma giants could be insulated from Trump's drug tariffs

CNBC · Just In
CNBC
CNBC
Just In

CNBC's Silvia Amaro looks at how investors around the world are digesting news of President Donald Trump's 100% tariff on branded drugs, and whether Europe's pharma giants will avoid the worst impact.

Breakdown
  • The US will impose a 100 percent tariff on branded drug imports, with exemptions for companies building US plants. 13s
  • European pharma firms are expected to be insulated from these tariffs due to the US-EU trade deal. 45s
  • Major European companies like AstraZeneca, Roche, and Novartis have announced significant investments in US manufacturing. 1m 3s
  • JP Morgan analysts say most large-cap European biopharma companies will largely avoid the new tariffs. 1m 27s
  • Industry executives report sufficient US manufacturing capacity and positive trade balances, minimizing tariff impact. 1m 54s
BusinessForeign Affairs